Molecular Data Generation a Clinical Follow-up within the International Molecular Neuropathology Registry
","eudractNumber":null,"id":6166,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2020-11-11T12:25:41+01:00","shortTitle":"MNP Int-R","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A prospective randomized, double-blind, placebo-controlled, multi-center phase III study to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic cell transplantation (HCT)","eudractNumber":"2021-002864-36","id":10399,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":"NCT05429632","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-05-25T08:46:36+02:00","shortTitle":"MOTRANS - PKRPC001","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"MPN Childhood Registry","eudractNumber":null,"id":11998,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2026-04-27T11:49:21+02:00","shortTitle":"MPN Childhood Registry","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Ohrakupressur bei Patienten mit Multiplem Myelom - eine randomisierte kontrollierte Studie","eudractNumber":null,"id":8932,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05762250","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-08-17T11:04:30+02:00","shortTitle":"MY_ACU","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"International, multicenter, non-interventional PASS study to evaluatemthe effectiveness and safety of elranatamab in patients with relapsed/refractory multiple myelom treated in real world settings","eudractNumber":null,"id":11259,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-08-01T10:04:25+02:00","shortTitle":"MagnetisMM-16","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation","eudractNumber":"2021-002531-27","id":10386,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05243797","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-08-29T14:00:40+02:00","shortTitle":"MajesTEC-4","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC \nand Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and \nLenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in \nParticipants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended \nfor Autologous Stem Cell Transplant as Initial Therapy ","eudractNumber":"2022-000909-28","id":9487,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05552222","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-06-01T14:01:36+02:00","shortTitle":"MajesTEC-7, 64007957MMY3005","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"
MEGA-Studie - Minimal invasive versus offene Gastrektomie. Eine multizentrische randomisierte kontrollierte Studie
DRKS00025765
","eudractNumber":null,"id":9153,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-02-01T09:14:03+01:00","shortTitle":"Mega Trial","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Genetische Veränderungen, Therapieansprechen und Resistenzentwicklung beim Melanom","eudractNumber":null,"id":2136,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2014-11-20T09:42:29+01:00","shortTitle":"Melanom Sequenzierungsprojekt (Melaseq)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Machbarkeitsstudie zu Einfluss des intestinalen Mikrobioms auf die Anastomosenheilung nach chirurgischer Resektion beim Rektumkarzinom","eudractNumber":null,"id":10461,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2025-01-28T12:44:44+01:00","shortTitle":"MikroRectum","therapeutical":false,"therapyLines":[]}]}